^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cladribine

    i
    Other names: 2-CdA, 2-Chlorodeoxyadenosine, Chlorodeoxyadenosine, Intocel, Leustatine, N-l-Leucyl-doxorubicin
    Company:
    Generic mfg.
    Drug class:
    Purinergic receptor P1 agonist
    6d
    Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. (PubMed, Cancer)
    Collectively, these findings suggest that ASXL1MUT AML may be more appropriately classified as intermediate risk in the context of LIT+VEN-based therapy, with the depth of impact influenced by the specific LIT backbone.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    TP53 mutation • FLT3-ITD mutation • RAS mutation • ASXL1 mutation
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    16d
    CEREAL: Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes (clinicaltrials.gov)
    P1, N=29, Recruiting, Institut Paoli-Calmettes | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cladribine • fludarabine IV • busulfan
    16d
    Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. (PubMed, Am J Hematol)
    The combination produced a high rate of remissions, translating into favorable outcomes for older patients with newly diagnosed AML. Trial Registration: ClinicalTrials.gov idetifier: NCT03586609.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine
    18d
    Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature review. (PubMed, Anticancer Drugs)
    This case suggests that the combination of cladribine and low-dose rituximab may be an effective therapeutic strategy for classical HCL with TP53 abnormality, enabling deep molecular response and reversal of associated bone marrow fibrosis. Further prospective studies are warranted to validate these findings.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • TP53 deletion
    |
    Rituxan (rituximab) • cladribine
    25d
    RG1121403: Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms (clinicaltrials.gov)
    P1/2, N=62, Recruiting, University of Washington | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • mitoxantrone • cladribine • Starasid (cytarabine ocfosfate)
    27d
    042011: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis (2024-512676-36-00)
    P2/3, N=1124, Active, not recruiting, St. Anna Childrens Cancer Research Institute GmbH | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • methotrexate • cladribine • melphalan • fludarabine IV • mercaptopurine • vinblastine • prednisolone
    1m
    A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation • Chr del(5q)
    |
    cytarabine • azacitidine • cladribine • melphalan • busulfan
    2ms
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=289, Recruiting, Medizinische Hochschule Hannover | N=128 --> 289
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    2ms
    Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. (PubMed, Eur J Case Rep Intern Med)
    Aggressive mastocytosis can rarely present with diffuse osteoblastic bone lesions mimicking metastatic disease.Elevated serum tryptase and histopathological confirmation are essential for diagnosis, even when KIT mutations are absent.Early recognition prevents unnecessary oncologic investigations and allows timely initiation of cytoreductive therapy.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD68 (CD68 Molecule)
    |
    KIT mutation
    |
    cladribine
    2ms
    RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)
    P4, N=128, Recruiting, Medizinische Hochschule Hannover | N=52 --> 128
    Enrollment change • Minimal residual disease
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)
    3ms
    A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, University of Rochester
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    3ms
    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)